Ten minute daily PEMF inhibits hypoxia driven tumor angiogenesis and tumor growth (Williams et al. ’01 and Cameron et al. ’04) but does not inhibit non-hypoxia driven angiogenesis that normally occurs during embryogenesis and tail fin regeneration in Zebrafish (Short et al. ’05). Daily PEMF was found to retard angiogenesis and growth of a human breast cancer xenograph causing the tumor to develop proportionately larger areas of necrosis and hypoxia and smaller areas of proliferatively active cancer cells. It was also demonstrated that the daily PEMF therapy continued to inhibit tumor angiogenesis and tumor regrowth for two weeks following a standard course of ionizing radiation (IR) therapy (Cameron et al. ’04) however this PEMF therapy renders larger areas of the tumor hypoxic therefore is expected to lessen susceptibility to oxidative damage caused by further IR treatments or by oxidative dependent chemotherapy. This leads to the conclusion that PEMF is an effective adjunct therapy following IR therapy but that the continued daily PEMF therapy should be stopped sometime (perhaps 2-4 days) prior to a second round of IR therapy. The temporary cessation of PEMF prior to the second round of IR is necessary for resumption of angiogenesis, decrease of hypoxic areas and increase in proliferative active and well oxygenated areas within the tumor.

[Proc Amer Assoc Cancer Res, Volume 46, 2005]